Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
NEXTSTELLIS (Mayne Pharma International Pty Ltd)
Product name
NEXTSTELLIS
Date registered
Evaluation commenced
Decision date
Approval time
200 (255 working days)
Active ingredients
estetrol monohydrate; drospirenone
Registration type
NCE/NBE
Indication
NEXTSTELLIS (film-coated tablet) is indicated for use by women of reproductive potential to prevent pregnancy.